For citations:
Kurenkov A.L., Kuzenkova L.M., Bursagova B.I., Chernikov V.V., Agranovich O.V., Khachatryan L.G., Kenis V.M., Zherebtsova V.A., Sarzhina M.N., Odinaeva N.D., Artemenko A.R., Popova G.A., Moroshek E.A., Tabe E.E., Nezhelskaya A.A., Maksimenko A.A., Akhadova L.Y., Indereikin M.V., Duibanova N.V., Tikhonova L.V., Sapogovskiy A.V., Gadzhialieva Z.M., Grigorieva A.V., Perminov V.S., Fedonyuk I.D., Kolpakchi L.M., Kursakova A.Yu., Tsurina N.A. Russian consensus on the use of incobotulinumtoxinA in children with cerebral palsy for the treatment of spasticity and sialorrhea. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(2):117-125. https://doi.org/10.14412/2074-2711-2022-2-117-125
Email this article 